Application of Dual PI-3K/mTOR Inhibitors Is Not Always Superior to Inhibition of mTOR Alone

被引：1
作者：
Wong, Jacky [1 ]
Welschinger, Robert [1 ]
Baraz, Rana [1 ]
Bradstock, Kenneth Francis [2 ]
Bendall, Linda J. [3 ]
机构：
[1] Westmead Millenium Inst, Westmead Inst Canc Res, Sydney, NSW, Australia
[2] Westmead Hosp, Westmead, NSW 2145, Australia
[3] Westmead Millennium Inst, Westmead, NSW, Australia
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.3575.3575
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1526 / 1526
页数：1
相关论文
共 50 条
  • [1] Comparision of Dual PI-3K/mTOR Inhibitors with mTOR Inhibitors Using a Pre-Clinical Model of Acute Lymphoblastic Leukemia
    Wong, Jacky
    Welschinger, Robert
    Baraz, Rana
    Weiss, Jocelyn
    Bradstock, Ken
    Bendall, Linda J.
    BLOOD, 2010, 116 (21) : 1336 - 1336
  • [2] Efficacy of dual PI-3K and mTOR inhibitors in Vitro and in Vivo in acute lymphoblastic leukemia
    Wong, Jacky
    Welschinger, Robert
    Hewson, John
    Bradstock, Kenneth F.
    Bendall, Linda J.
    ONCOTARGET, 2014, 5 (21) : 10460 - 10472
  • [3] Direct inhibition of mTOR may be detrimental when combining mTOR inhibitors or dual PI3 kinase/mTOR inhibitors with paclitaxel
    Bhattacharya, Bhaskar
    Richardson, Alan
    Sain, Nivedita
    Ormerod, Michael
    Kaye, Stanley
    Workman, Paul
    Jackman, Ann
    CANCER RESEARCH, 2008, 68 (09)
  • [4] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
    Chen, Jiezhong
    Zhao, Kong-Nan
    Li, Rui
    Shao, Renfu
    Chen, Chen
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
  • [5] Design and synthesis of dual PI3K/mTor inhibitors
    Olivero, Alan
    Heffron, Timothy
    Berry, Leanne
    Berry, Megan
    Castanedo, Georgette
    Chang, Christine
    Dotson, Jennafer
    Friedman, Lori
    Goldsmith, Richard
    Lesnick, John
    Lewis, Cristina
    Mathieu, Simon
    Nonomiya, Jim
    Pang, Jodie
    Peterson, David
    Prior, Wei Wei
    Salphati, Laurent
    Sampath, Deepak
    Sutherlin, Daniel
    Tsui, Vickie
    Ultsch, Mark
    Wang, Shumei
    Wiesmann, Christian
    Wong, Susan
    Zhu, Bing-Yan
    Chuckowree, Irina
    Folkes, Adrian
    Shuttleworth, Steve
    CANCER RESEARCH, 2009, 69
  • [6] Dual PI3K and mTOR Inhibition in Waldenstrom Macroglobulinemia
    Husu, E. N.
    Roccaro, A. M.
    Anderson, K. C.
    Ghobrial, I. M.
    Leleu, X.
    Sacco, A.
    Melhem, M. R.
    Azab, A. K.
    Jia, X.
    Ngo, H. T.
    Azab, F.
    Runnels, J.
    Quang, P.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S144 - S145
  • [7] Inhibition of mTOR, but not PI3K, is required for the anti-tumor efficacy in breast cancer of dual PI3K/mTOR inhibitors given in combination with MEK inhibitors
    Smith, Aleisha M.
    Xiong, Jessie
    Hunter, Lucas
    Jordan, Jamie
    Clark, Kelly
    Darr, David B.
    Norman, Sharpless
    Perou, Charles M.
    Kim, William Y.
    CANCER RESEARCH, 2015, 75
  • [8] Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors
    Alvarez, Rosa M.
    Belen Garcia, Ana
    Riesco-Fagundo, Concepcion
    Martin, Jose, I
    Varela, Carmen
    Rodriguez Hergueta, Antonio
    Gonzalez Cantalapiedra, Esther
    Oyarzabal, Julen
    Di Geronimo, Bruno
    Lorenzo, Milagros
    Isabel Albarran, M.
    Cebria, Antonio
    Cebrian, David
    Martinez-Gonzalez, Sonia
    Blanco-Aparicio, Carmen
    Pastor, Joaquin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 211
  • [9] Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
    Sabbah, D. A.
    Brattain, M. G.
    Zhong, H.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (36) : 5528 - 5544
  • [10] Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML
    Herschbein, Lauren
    Liesveld, Jane L.
    BLOOD REVIEWS, 2018, 32 (03) : 235 - 248
12345